omniture

Biovaxys Strengthens Internal Expertise With Appointment Of Scientific Advisor For Ovarian Cancer Vaccine Clinical Program And Papilocare Marketing

BioVaxys Technology Corp.
2021-05-24 20:00 5172

VANCOUVER, British Columbia, May 24, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, US OTCQB: BVAXF) ("BioVaxys" or "the Company") is pleased to announce that Charles J. Dunton, MD, has joined BioVaxys as an Advisor to help provide additional scientific support for BVX-0918A, the Company's ovarian cancer vaccine candidate, and its planned marketing and sale of Papilocare in the United States.

Dr. Dunton, a top global opinion leader, is a gynecologist/oncologist in Indiana. He received his medical degree from Jefferson Medical College and has been in practice for more than 30 years.  Dr. Dunton has been Chief, Division of Gynecologic Oncology Department of Obstetrics and Gynecology, Main Line Health and Professor, Department of Obstetrics and Gynecology, Jefferson Medical College, and has been named one of America's Top Doctors for Cancer by U.S. News & World Report.  His clinical background and research interests match those of BioVaxys and include ovarian cancer, cervical cancer, and human papillomavirus ("HPV").  He is Past President and board member of the American Society for Colposcopy and Cervical Pathology and was on the Editorial Board of the Journal of Lower Genital Tract Disease.  Dr Dunton is familiar with BVX-0918A, having been involved in the early clinical trials of the first generation of the vaccine at Thomas Jefferson University. Most recently, he was Global Medical Director, Aspira Women's Health (NASDAQ:AWH).

"I am very excited to join Biovaxys as an advisor for both the ovarian cancer vaccine and the treatment of cervical HPV" said Dr. Dunton.  "Ovarian cancer remains a deadly disease and the need for a novel treatment such as a vaccine is important."

Kenneth Kovan, President & Chief Operating Office of BioVaxys, added "We are delighted to welcome Dr. Dunton to our team.  Dr Dunton and Dr David Berd, BioVaxys Chief Medical Officer, have previously worked together at Thomas Jefferson University on Dr. Berd's clinical trials of the first generation of our ovarian cancer vaccine. Dr. Dunton's clinical experience makes him ideally suited to bring additional strategic guidance to BioVaxys as we advance BVX-0918A, our ovarian cancer vaccine candidate, into a EU clinical study, and our planned marketing and sale of Papilocare in the United States."

About BioVaxys Technology Corp.

Based in Vancouver, BioVaxys Technology Corp., a British Columbia-registered clinical-stage biotechnology company, is developing viral and oncology vaccines based on its proprietary hapten-conjugated antigen platforms as well as immuno-diagnostics.  The Company is developing BVX-0320, its SARS-CoV-2 vaccine candidate, and is advancing a clinical study of BVX-0918A, its cancer vaccine in combination with anti-PD1 and anti-PDL-1 checkpoint inhibitors, in late-stage ovarian cancer. Also in development is a diagnostic for evaluating the presence or absence of a T-cell immune response to SARS-CoV-2.  BioVaxys has two issued US patents and multiple pending US and international patents related to its cancer vaccine platform, and US/PCT patent applications for its viral vaccine platform and diagnostic technologies. BioVaxys common shares trade on the CSE under the stock symbol "BIOV" and are listed on the Frankfurt Bourse (FRA: 5LB) and the OTCQB Venture Market (OTCQB: BVAXF).

Cautionary Statements Regarding Forward Looking Information

This press release includes certain "forward-looking information" and "forward-looking statements" (collectively "forward-looking statements") within the meaning of applicable Canadian and United States securities legislation including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein, without limitation, statements relating the future operating or financial performance of the Company, are forward looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that events, conditions, or results "will", "may", "could", or "should" occur or be achieved. Forward-looking statements in this news release relate to, among other things, completion of the murine model study, regulatory approval for a Phase I study of its BVX-0320 Vaccine Candidate in humans and the overall development of BioVaxys' vaccines, including any haptenized SARS-Cov-2 protein vaccine. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied in such forward-looking statements.

These forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies including, primarily but without limitation, the risk that BioVayxs' vaccines will not prove to be effective and/ or will not receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about whether its products will complete the long, complex and expensive clinical trial and regulatory approval process for approval of new drugs necessary for marketing approval, uncertainty about whether its autologous cell vaccine immunotherapy can be developed to produce safe and effective products and, if so, whether its vaccine products will be commercially accepted and profitable, the expenses, delays and uncertainties and complications typically encountered by development stage biopharmaceutical businesses, financial and development obligations under license arrangements in order to protect its rights to its products and technologies, obtaining and protecting new intellectual property rights and avoiding infringement to third parties and their dependence on manufacturing by third parties.

The Company does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

ON BEHALF OF THE BOARD
Signed "James Passin"
James Passin, CEO
+1 646 452 7054

Media Contacts BioVaxys Technology Corp.

Nikita Sashdev
Luna PR
info@lunapr.io

Logo - https://mma.prnasia.com/media2/1430981/BIOVAXYS_Logo.jpg?p=medium600

Source: BioVaxys Technology Corp.
collection